Latest news with #CTRI
San Francisco Chronicle
06-08-2025
- Business
- San Francisco Chronicle
Centuri: Q2 Earnings Snapshot
PHOENIX (AP) — PHOENIX (AP) — Centuri Holdings Inc. (CTRI) on Wednesday reported profit of $8.1 million in its second quarter. On a per-share basis, the Phoenix-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 19 cents per share. The utility infrastructure services provider posted revenue of $724.1 million in the period. _____
News18
16-07-2025
- Health
- News18
Can Cholesterol-Lowering Drugs Treat Cancer? Indian Scientists Begin Tests After Positive Mice Data
Last Updated: Anecdotal and epidemiological evidence has also suggested that people taking statins regularly may have a lower risk of developing solid tumours such as colorectal or breast cancer Cholesterol-lowering statins, long trusted to protect hearts, may soon find a new role in cancer care — this time, as a potential ally in shrinking tumours. A team led by Dr Sanjeev Galande, dean of the School of Natural Sciences at Shiv Nadar University and one of India's leading cell biologists and epigeneticists, is repurposing statins to treat colorectal, breast and other solid cancers. In collaboration with the Tata Memorial Centre, a multi-phase clinical trial involving 350 patients is underway to evaluate the drug's cancer-fighting potential. The ongoing trial, which bypassed early-stage studies due to strong pre-clinical evidence, is comparing two groups: one receiving standard therapy (chemotherapy plus radiation), and another receiving statins as part of the regimen. Patient recruitment began in 2022, with results expected to be submitted for publication in the next few months. 'Our pre-clinical studies in animal models were promising. We induced tumour formation in mice and treated them with statins. Not only did the visible tumour lumps begin regressing, but molecular and cellular studies confirmed that statins reversed the tumorigenic process," Galande told News18. 'These drugs altered the molecular signature of cancer cells—switching off proteins that drive tumour growth and pushing cells back toward a normal state." The findings in mice, published in Oncotarget medical journal on Tuesday, showed how statins affected gene and protein expression in tumours, with data derived from dissected tissues and molecular assays. The samples were collected from patients via colonoscopy and flash-frozen in liquid nitrogen before undergoing analysis. 'Importantly, anecdotal and epidemiological evidence has also suggested that people taking statins regularly may have a lower risk of developing solid tumours such as colorectal or breast cancer — though the effect does not appear to extend to blood cancers like leukemia, which follow different biological pathways," explained Galande, who is among India's most-decorated molecular biologists and a key 'torch-bearer of Indian bioscience". According to the trial protocol published on Clinical Trials Registry (CTRI), the success of the study would bring a low-cost, low-risk intervention in the form of statins that could 'potentially lead to the refinement of strategies, such as 'watch and wait', in a select subgroup of patients". Clinical Trial On Humans Likely To Conclude Soon Currently, colorectal cancer is the third most common cancer in men and the second in women worldwide. In India, it is the third most common cancer. In India, the annual incidence rates for colon cancer and rectal cancer in men are 4.4 and 4.1 per 100,000, respectively. The standard treatment for locally advanced rectal cancer is chemotherapy and radiation therapy followed by surgery. Galande's team, backed by funding from the Department of Biotechnology (DBT), believes the implications of this research could extend to cancer prevention. 'Once the study on humans is peer-reviewed and published, statins could be explored as a precautionary treatment for individuals with a hereditary risk of cancer, given their well-established safety profile," he said. Under the trial, patients are given 20mg rosuvastatin—a popular statin—orally. The team also plans to investigate whether statins can help prevent metastasis in advanced cancers, particularly in secondary sites like the liver. If successful, this could open new avenues for affordable cancer therapy using an existing, widely available drug. 'The project began in 2019 but was temporarily stalled by the Covid-19 pandemic," Galande said, adding: 'However, the accelerated translation from lab to clinic has put it back on track — and statins may soon graduate from cholesterol management to tumour management." view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
28-06-2025
- Business
- Yahoo
Centuri Holdings (CTRI) Surges Amid New Contract Awards
The share price of Centuri Holdings, Inc. (NYSE:CTRI) surged by 8.24% between June 18 and June 26, 2025, putting it among the Energy Stocks that Gained the Most This Week. A large natural gas pipeline snaking through a rural landscape. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) surged this week after the company announced that it had secured more than $575 million in infrastructure contract awards across the United States, reflecting its momentum in capturing opportunities to expand and modernize essential energy infrastructure. A significant portion of the announced awards includes a multi-year contract renewal with a long-standing natural gas utility customer for gas distribution, transmission, and storage services. The new projects complement the $350 million in awards Centuri Holdings, Inc. (NYSE:CTRI) previously announced last month. While we acknowledge the potential of CTRI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Nuclear Energy Stocks to Buy Right Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-06-2025
- Business
- Yahoo
Centuri Holdings (CTRI) Fell This Week. Here is Why.
The share price of Centuri Holdings, Inc. (NYSE:CTRI) fell by 8.63% between June 10 and June 17, 2025, putting it among the Energy Stocks that Lost the Most This Week. A large natural gas pipeline snaking through a rural landscape. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) fell this week after the company announced that it has commenced an underwritten secondary public offering of 9.5 million shares of CTRI's common stock by Southwest Gas as a selling stockholder. Southwest also intends to grant underwriters a 30-day option to purchase up to an additional 1.425 million shares. However, Centuri will not receive any proceeds from the offering as it is not selling any shares. Moreover, Southwest Gas has separately also entered into an agreement to sell $22 million in CTRI shares to investment entities affiliated with Carl C. Icahn in a concurrent private placement at the same price as the public offering. While we acknowledge the potential of CTRI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Nuclear Energy Stocks to Buy Right Now and Disclosure: None.
Yahoo
06-06-2025
- Business
- Yahoo
Centuri Holdings (CTRI) Surged This Week. Here is Why.
The share price of Centuri Holdings, Inc. (NYSE:CTRI) surged by 9.74% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A close-up of an electrical power line with a bright blue sky in the background, highlighting the company's selection of electricity and natural gas services. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) continues to surge after the company announced $350 million in new customer awards in late May, reflecting strong demand for the company's infrastructure solutions across North America. The awards span the United States and include work supporting electric and gas infrastructure modernization, water relocation, utility distribution, and renewables. This comes after Centuri Holdings had already announced nearly $490 million in multi-year customer awards earlier this year. The share price of Centuri Holdings, Inc. (NYSE:CTRI) has gained almost 23% over the last month. While we acknowledge the potential of CTRI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
